University Eye Hospital Tuebingen, Centre for Ophthalmology, Elfriede-Aulhorn-Str. 7, Tübingen, 72076, Germany.
Institute for Ophthalmic Research, Centre for Ophthalmology, Tuebingen, Germany.
Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3661-3670. doi: 10.1007/s00417-024-06508-8. Epub 2024 May 21.
Preserflo MicroShunt is a novel microinvasive bleb forming device for the treatment of primary open-angle glaucoma. The intermediate- and long-term success and the impact of this procedure on corneal endothelial cell density remain to be investigated.
In this prospective observational study, 62 eyes of 55 glaucoma patients (mean age ± SD: 67.0 ± 15.0 years) receiving a Preserflo MicroShunt were included. Corneal endothelial cell density, intraocular pressure and best corrected visual acuity were assessed preoperatively and at 3, 6, 9, 12, 18 and 24 months postoperatively. Success rates, bleb revision rates and complications were analysed. Complete success was defined as an intraocular pressure reduction of ≥ 20% and achieving a target pressure of ≤ 18, ≤ 15 or ≤ 12 mmHg without antiglaucoma medication. Qualified success indicated that the criteria were reached with or without medication.
Corneal endothelial cells showed no significant decline over 24 months (p > 0.05). Intraocular pressure showed a substantial reduction postoperatively (p < 0.001), decreasing from 29.6 ± 8,3 mmHg to 13.0 ± 4.3 mmHg after 24 months (p < 0.001). Complete and qualified success with a target pressure ≤ 15 mmHg was achieved in 52.9% and 54.6% of cases after 24 months, respectively. Best corrected visual acuity did not change after 24 months.
Preserflo MicroShunt had no negative side effects on corneal endothelial cells and showed favourable success rates after 2 years in patients with open-angle glaucoma.
Preserflo MicroShunt 是一种新型微创滤泡形成装置,用于治疗原发性开角型青光眼。该手术的中期和长期成功率以及对角膜内皮细胞密度的影响仍有待研究。
在这项前瞻性观察研究中,纳入了 55 名青光眼患者(67.0±15.0 岁)的 62 只眼,这些患者接受了 Preserflo MicroShunt 治疗。术前和术后 3、6、9、12、18 和 24 个月评估角膜内皮细胞密度、眼内压和最佳矫正视力。分析成功率、滤泡修正率和并发症。完全成功定义为眼内压降低≥20%,并达到目标眼压≤18、≤15 或≤12mmHg,无需抗青光眼药物。合格成功表示在有或没有药物的情况下达到了标准。
术后 24 个月内角膜内皮细胞无明显下降(p>0.05)。术后眼内压显著降低(p<0.001),从 29.6±8.3mmHg 降至 24 个月时的 13.0±4.3mmHg(p<0.001)。术后 24 个月,目标眼压≤15mmHg 的完全成功率和合格成功率分别为 52.9%和 54.6%。术后 24 个月最佳矫正视力无变化。
Preserflo MicroShunt 对角膜内皮细胞没有负面影响,在 2 年的时间内,对开角型青光眼患者显示出良好的成功率。